GIM
RMD icon

Glenmede Investment Management’s ResMed RMD Stock Holding History

Glenmede Investment Management’s Portfolio RMD Stock Details RMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$1.4M Buy
5,131
+100
+2% +$27.3K 0.01% 625
2025
Q2 		$1.3M Buy
+5,031
New +$1.2M 0.01% 649

Other funds holding RMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Glenmede Investment Management's RMD Position: Q3 2025 in Review

Glenmede Investment Management increased its ResMed (RMD) stake by 2% in Q3 2025, buying an estimated $27.3K and bringing the position to 5,131 shares worth $1.4M. The position accounts for 0.01% of the portfolio, ranked #625.

Glenmede Investment Management first reported a position in RMD in Q2 2025 and has held it in 2 quarters since. 949 funds tracked by Wall St. Rank hold RMD as of Q3 2025.

  • Glenmede Investment Management held 5,131 shares of ResMed worth $1.4M as of Q3 2025.
  • Glenmede Investment Management bought 100 ResMed shares in Q3 2025, an estimated $27.3K.
  • ResMed made up 0.01% of Glenmede Investment Management's portfolio in Q3 2025, its #625 holding.
  • Glenmede Investment Management first reported a position in ResMed in Q2 2025 and has held it in 2 quarters since.
  • 949 funds tracked by Wall St. Rank held ResMed as of Q3 2025.

Based on Glenmede Investment Management's 13F filing for Q3 2025, filed 13 Nov 2025.